On Wednesday, Shares of Republic Airways Holdings Inc. (NASDAQ:RJET), surged 52.91% to $5.26.
Republic Airways Holdings declared preliminary second quarter 2015 results.
Preliminary Second Quarter 2015 Results
The Company anticipates to report second quarter net income of $4.0 to $5.0 million or $0.08 to $0.10 per diluted share, and pretax margins of 2.5% to 3.0% on operating revenues of $338 to $340 million. The second quarter results were negatively influenced by, among other factors, an operation that produced about 4% fewer block hours than forecasted due to the ongoing operational disruption caused by regulatory changes and further intensified by our ongoing pilot labor dispute.
Republic Airways Holdings Inc., through its auxiliaries, provides planned passenger services. The company offers planned passenger service on about 1,229 flights daily to about 101 cities in the U.S. and Canada.
Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA), declined -0.74% to $70.88, during its last trading session.
Teva Pharmaceutical declared that it has successfully filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for reslizumab. Reslizumab is a humanized anti-interleukin-5 (IL-5) monoclonal antibody (mAb) for the treatment of inadequately controlled asthma in adult patients with elevated blood eosinophils, despite an inhaled corticosteroid (ICS)-based regimen.
The MAA for reslizumab comprises data from Teva’s Phase III BREATH clinical trial program. The program compriseed of four separate placebo-controlled Phase III trials specifically designed to comprise a targeted population of 1,700 adult and adolescent asthma patients with elevated blood eosinophils, whose symptoms were inadequately controlled with inhaled corticosteroid-based therapies. Results from these studies demonstrated that reslizumab, contrast to placebo, reduced asthma exacerbation rates by at least half (50-60 percent) and offered noteworthy improvement in lung function, quality of life and other secondary measures of asthma control as add-on therapy. Common adverse events in the reslizumab treatment group were comparable to placebo and comprised of worsening of asthma, nasopharyngitis, upper respiratory infections, sinusitis, influenza and headache. Two anaphylactic reactions were stated and resolved following medical treatment at the study site.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients.
Finally, Sonus Networks, Inc. (NASDAQ:SONS), ended its last trade with 12.07% surge, and closed at $6.87.
Sonus Networks declared results for the second quarter ended June 26, 2015.
Second Quarter 2015 Highlights
- Total Company revenue was $54.7 million, contrast to $75.6 million in the second quarter of 2014.
- Product revenue was $27.0 million, contrast to $45.8 million in the second quarter of 2014.
- Service revenue was $27.7 million, contrast to $29.7 million in the second quarter of 2014.
- Indirect (channel) represented 26% of product revenue, contrast to 29% in the second quarter of 2014.
- Enterprise represented 22% of product revenue, contrast to 20% in the second quarter of 2014.
- GAAP gross margin was 62.9%; non-GAAP gross margin was 65.9%.
- GAAP operating expenses were $49.5 million; non-GAAP operating expenses were $40.9 million.
- GAAP loss per share was $0.31; non-GAAP loss per share was $0.10.
- Cash and investments were $113.5 million.
Sonus Networks, Inc. provides networked solutions for communications service providers and enterprises. Its products comprise session border controllers (SBC) that address the network requirements for small, medium, and large businesses, in addition to for communications service providers; and open services switches for converting various types of voice signals into Internet protocol (IP) packets and transmitting those IP packets over a data network.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
